Grail secured $325 million in a private placement to bolster its balance sheet ahead of regulatory filings for its multi‑cancer blood test. The company also released Pathfinder 2 data showing improved performance over prior studies, and separate evidence suggests adding the Galleri test to routine screening could markedly increase early cancer detection rates. The financing aims to support regulatory engagement and commercial preparation as Grail seeks approvals and payer conversations. Regulators and payers will scrutinize sensitivity, positive predictive value, and downstream workflows; Grail’s ability to demonstrate clinical utility and cost‑effective deployment will be critical for adoption.